CK Merck & Company: Evaluating a Drug Licensing Opportunity Rich Kender, Vice President of Financial Evaluation & Analysis at Merck, was working with his team to decide whether his company should license Davanrik, a new drug with the potential to treat both depression and obesity. The small pharmaceutical concern that developed the drug, LAB Pharmaceuticals, lacked the resources to complete the lengthy approval process, manufacture the compound, and market the drug. LAB had approached Merck with
Words: 2375 - Pages: 10
Name: Anila B. Merck is a very large pharmaceutical company. One of the scientists at Merck realized that Merck’s new drug for de-worming animals from parasites could also help fighting against river blindness, which is a disease that has hit places of most poverty. River blindness is a skin disease, which is transmitted by the bite of blackflies. This parasite can migrate into the eye and cause blindness. Unfortunately those who get the disease do not have the money to pay for this drug. The countries
Words: 926 - Pages: 4
The context contemporary global business environment s requires companies to keep up with the pace of rapid changes and to meet financial expectations of numerous stakeholders. However these expectations are not financial only. Growing environmental concerns, depleting natural resources, globalisation issues, political and social instability require companies to reconsider their change management practices to comply with stakeholders expectations Pharmaceutical industry is no exception. The pharmaceutical
Words: 6651 - Pages: 27
RUBACK Merck & Company: Evaluating a Drug Licensing Opportunity Rich Kender, Vice President of Financial Evaluation & Analysis at Merck, was working with his team to decide whether his company should license Davanrik, a new drug with the potential to treat both depression and obesity. The small pharmaceutical concern that developed the drug, LAB Pharmaceuticals, lacked the resources to complete the lengthy approval process, manufacture the compound, and market the drug. LAB had approached Merck with
Words: 2360 - Pages: 10
Merck Josue Vazquez University of Phoenix Management - MGT/ 521 Dr. Hector Torres Perez February 19, 2014 Merck The history of Merck Company as one of the first pharmaceutical in the world dates all the way back to 1668 when Friedrich Jacob Merck acquired the Angel Pharmacy, which became the heart of Merck and is still owned by the Merck family today. In 1891 Merck in Germany became Merck KGAA or "German
Words: 1148 - Pages: 5
Introduction Merck was established in the U.S. in 1891, but its roots trace back to Friedrich Jacob Merck’s purchase of a German drug store in 1668. Today the company is a top tier global entity, a “research-driven” pharmaceutical company “dedicated to putting patients first.” Merck’s mission is to “provide society with superior products that improve the quality of life and satisfy customer needs, provide employees with meaningful work and investors with a superior rate of return.” As a long time
Words: 492 - Pages: 2
Ugochukwu.M.Duru Date: 09/22/2015 Article #: 5 Title: Germany’s Merck to buy Sigma-Aldrich For $17 Billion Publication Name: Wall Street Journal Publication Date: 09/22/2014 According to this article Merck KGaA announced On Monday September 22, 2014, that it would acquire Sigma-Aldrich for $17 billion. This acquisition will boost Merck’s position in the global life sciences industry, which is valued at over $130 billion. Merck expects the deal to generate $340 million in synergies by the end
Words: 564 - Pages: 3
Stake for Vagelos as CEO and for Merck as a company in deciding whether to invest in Dr. Campbell’s idea Although Dr. Campbell’s idea of a drug (Ivermectin) that could cure River blindness was a path-breaking opportunity for Merck, the company was faced with a number of ethical, financial and moral issues that forced its CEO to undergo deep thought and contemplation before investing in this idea. * Feasibility: There were concerns about the use of this drug on humans and the potential adverse
Words: 565 - Pages: 3
Pfizer (PFE) Financial Analysis for 2012, 2013 and 2014: Ratio Analysis Abstract The following is a list of these ratios, in conjunction with associative details and background to itemize and explicate the overall financial enquiry: Earnings per Share (EPS), which will illustrate current, along with expected, product losses, unfavorable impact and any adverse change in a foreign exchange rate, along with adjustable income attributable to Pfizer and its shareholder's guidance. The next ratio
Words: 1814 - Pages: 8
I believe neither Merck nor Pfizer acted ethically or socially responsible during the Vioxx disaster. Evidence suggests that Merck might have knows about the harmful side effects of Vioxx and yet they hesitated for over 3 years to recall the drug. There was also an allegation that the company had manipulated and covered-up the results of the medical trials in their favor. An ethical thing to do would be to simultaneously recall the drug as well as inform the public about the dangers of using Vioxx
Words: 517 - Pages: 3
